$PALI
PALISADE BIO, INC.

2014 Q2 Form 10-Q Financial Statement

#000114420414029264 Filed on May 12, 2014

View on sec.gov

Income Statement

Concept 2014 Q2 2014 Q1 2013 Q1
Revenue $5.000K $4.167K $102.5K
YoY Change 100.0% -95.93% -34.4%
Cost Of Revenue
YoY Change
Gross Profit
YoY Change
Gross Profit Margin
Selling, General & Admin $1.520M $3.520M $1.200M
YoY Change 18.75% 193.33% 3.45%
% of Gross Profit
Research & Development $2.000M $1.630M $1.748M
YoY Change 4.91% -6.75% 22.92%
% of Gross Profit
Depreciation & Amortization $90.00K $90.00K $50.00K
YoY Change 80.0% 80.0% 66.67%
% of Gross Profit
Operating Expenses $3.516M $5.181M $2.994M
YoY Change 8.59% 73.03% 14.31%
Operating Profit -$3.511M -$5.177M -$2.892M
YoY Change 8.52% 79.02% 17.4%
Interest Expense $397.6K $432.7K $48.26K
YoY Change -9.48% 796.74% 5557.33%
% of Operating Profit
Other Income/Expense, Net -$3.240M -$742.2K -$698.3K
YoY Change 7.43% 6.28% -6791.97%
Pretax Income -$6.750M -$5.920M -$3.590M
YoY Change 8.0% 64.9% 46.53%
Income Tax $0.00
% Of Pretax Income
Net Earnings -$6.751M -$5.919M -$3.590M
YoY Change 7.99% 64.87% 46.37%
Net Earnings / Revenue -135025.64% -142046.0% -3502.52%
Basic Earnings Per Share
Diluted Earnings Per Share -$112.5M -$118.4M -$89.75M
COMMON SHARES
Basic Shares Outstanding 86.76M shares 86.22M shares
Diluted Shares Outstanding

Balance Sheet

Concept 2014 Q2 2014 Q1 2013 Q1
SHORT-TERM ASSETS
Cash & Short-Term Investments $30.23M $33.34M $12.66M
YoY Change 170.64% 163.35% 146.3%
Cash & Equivalents $15.23M $18.34M $12.66M
Short-Term Investments $15.00M $15.00M
Other Short-Term Assets $590.0K $760.0K $880.0K
YoY Change -27.16% -13.64% 39.68%
Inventory
Prepaid Expenses $196.2K $319.6K
Receivables $24.47K $11.36K
Other Receivables $0.00 $0.00
Total Short-Term Assets $30.84M $34.11M $13.54M
YoY Change 157.64% 151.91% 134.13%
LONG-TERM ASSETS
Property, Plant & Equipment $310.1K $310.4K $210.0K
YoY Change 63.34% 47.8% -21.17%
Goodwill
YoY Change
Intangibles $1.247M $1.191M
YoY Change 26.66%
Long-Term Investments
YoY Change
Other Assets $58.86K $64.85K $780.0K
YoY Change -1.19% -91.69% 934.57%
Total Long-Term Assets $1.786M $1.815M $1.870M
YoY Change -2.23% -2.97% 75.88%
TOTAL ASSETS
Total Short-Term Assets $30.84M $34.11M $13.54M
Total Long-Term Assets $1.786M $1.815M $1.870M
Total Assets $32.63M $35.92M $15.41M
YoY Change 136.47% 133.12% 125.08%
SHORT-TERM LIABILITIES
YoY Change
Accounts Payable $2.030M $1.770M $1.240M
YoY Change 150.62% 42.74% -24.85%
Accrued Expenses $410.0K
YoY Change -37.88%
Deferred Revenue
YoY Change
Short-Term Debt $0.00 $0.00 $0.00
YoY Change
Long-Term Debt Due $2.952M $2.850M $510.0K
YoY Change 138.93% 458.79%
Total Short-Term Liabilities $4.991M $4.674M $2.650M
YoY Change 66.03% 76.39% 14.62%
LONG-TERM LIABILITIES
Long-Term Debt $3.416M $4.193M $7.040M
YoY Change -46.32% -40.45%
Other Long-Term Liabilities $190.0K $160.0K $20.00K
YoY Change 216.67% 700.0%
Total Long-Term Liabilities $3.416M $4.193M $7.060M
YoY Change -46.32% -40.62%
TOTAL LIABILITIES
Total Short-Term Liabilities $4.991M $4.674M $2.650M
Total Long-Term Liabilities $3.416M $4.193M $7.060M
Total Liabilities $8.600M $9.027M $9.720M
YoY Change -8.76% -7.13% 320.4%
SHAREHOLDERS EQUITY
Retained Earnings -$141.1M -$134.3M
YoY Change 19.13%
Common Stock $868.4K $866.9K
YoY Change 22.99%
Preferred Stock
YoY Change
Treasury Stock (at cost)
YoY Change
Treasury Stock Shares
Shareholders Equity $24.03M $26.90M $5.690M
YoY Change
Total Liabilities & Shareholders Equity $32.63M $35.92M $15.41M
YoY Change 136.47% 133.12% 125.08%

Cashflow Statement

Concept 2014 Q2 2014 Q1 2013 Q1
OPERATING ACTIVITIES
Net Income -$6.751M -$5.919M -$3.590M
YoY Change 7.99% 64.87% 46.37%
Depreciation, Depletion And Amortization $90.00K $90.00K $50.00K
YoY Change 80.0% 80.0% 66.67%
Cash From Operating Activities -$2.410M -$2.710M -$2.510M
YoY Change -28.27% 7.97% 19.49%
INVESTING ACTIVITIES
Capital Expenditures -$170.0K $111.1K $1.656K
YoY Change 21.43% 6608.15% -105.52%
Acquisitions
YoY Change
Other Investing Activities $0.00 -$15.00M
YoY Change
Cash From Investing Activities -$170.0K -$15.22M -$100.0K
YoY Change 21.43% 15120.0% 247.61%
FINANCING ACTIVITIES
Cash Dividend Paid
YoY Change
Common Stock Issuance & Retirement, Net $20.00M
YoY Change
Debt Paid & Issued, Net $704.8K $0.00
YoY Change
Cash From Financing Activities -530.0K 19.43M 7.830M
YoY Change -126.5% 148.15% 59.1%
NET CHANGE
Cash From Operating Activities -2.410M -2.710M -2.510M
Cash From Investing Activities -170.0K -15.22M -100.0K
Cash From Financing Activities -530.0K 19.43M 7.830M
Net Change In Cash -3.110M 1.500M 5.220M
YoY Change 107.33% -71.26% 86.95%
FREE CASH FLOW
Cash From Operating Activities -$2.410M -$2.710M -$2.510M
Capital Expenditures -$170.0K $111.1K $1.656K
Free Cash Flow -$2.240M -$2.821M -$2.512M
YoY Change -30.43% 12.32% 21.3%

Facts In Submission

Frame Concept Type Concept / XBRL Key Value Unit
CY2014Q1 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
18342736 USD
CY2013Q4 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
16846052 USD
CY2014Q1 us-gaap Common Stock Value
CommonStockValue
866886 USD
CY2013Q4 us-gaap Common Stock Value
CommonStockValue
778860 USD
CY2014Q1 us-gaap Additional Paid In Capital
AdditionalPaidInCapital
160368948 USD
CY2013Q4 us-gaap Additional Paid In Capital
AdditionalPaidInCapital
136058135 USD
CY2014Q1 us-gaap Accumulated Other Comprehensive Income Loss Net Of Tax
AccumulatedOtherComprehensiveIncomeLossNetOfTax
5977 USD
CY2014Q1 us-gaap Use Of Estimates
UseOfEstimates
<div style="MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif "> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;BACKGROUND-COLOR: transparent; MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif"> <u>Use of Estimates</u></div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;BACKGROUND-COLOR: transparent; MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif" align="justify">The preparation of financial statements in accordance with U.S. GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the financial statements and the reported amounts of revenues and expenses during the reporting period. The condensed financial statements include significant estimates for the expected economic life and value of our licensed technology, our net operating loss and related valuation allowance for tax purposes and our stock-based compensation related to employees and directors, consultants and investment banks, among other things. Because of the use of estimates inherent in the financial reporting process, actual results could differ significantly from those estimates.</div> </div><table border="0" style="width:100%; table-layout:fixed;" cellspacing="0" cellpadding="0"><tr><td></td></tr></table>
CY2014Q1 us-gaap Accounts Receivable Net Current
AccountsReceivableNetCurrent
11359 USD
CY2013Q4 us-gaap Accounts Receivable Net Current
AccountsReceivableNetCurrent
10000 USD
CY2014Q1 us-gaap Deferred Finance Costs Current Net
DeferredFinanceCostsCurrentNet
435547 USD
CY2013Q4 us-gaap Deferred Finance Costs Current Net
DeferredFinanceCostsCurrentNet
507334 USD
CY2014Q1 us-gaap Prepaid Expense Current
PrepaidExpenseCurrent
319616 USD
CY2013Q4 us-gaap Prepaid Expense Current
PrepaidExpenseCurrent
255733 USD
CY2014Q1 us-gaap Assets Current
AssetsCurrent
34109258 USD
CY2013Q4 us-gaap Assets Current
AssetsCurrent
17619119 USD
CY2014Q1 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
310375 USD
CY2013Q4 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
230971 USD
CY2014Q1 us-gaap Intangible Assets Net Excluding Goodwill
IntangibleAssetsNetExcludingGoodwill
1190625 USD
CY2013Q4 us-gaap Intangible Assets Net Excluding Goodwill
IntangibleAssetsNetExcludingGoodwill
1137701 USD
CY2014Q1 us-gaap Deferred Finance Costs Noncurrent Net
DeferredFinanceCostsNoncurrentNet
248688 USD
CY2013Q4 us-gaap Deferred Finance Costs Noncurrent Net
DeferredFinanceCostsNoncurrentNet
360848 USD
CY2014Q1 us-gaap Other Assets Noncurrent
OtherAssetsNoncurrent
64850 USD
CY2013Q4 us-gaap Other Assets Noncurrent
OtherAssetsNoncurrent
64897 USD
CY2014Q1 us-gaap Assets
Assets
35923796 USD
CY2013Q4 us-gaap Assets
Assets
19413536 USD
CY2014Q1 us-gaap Accounts Payable And Accrued Liabilities Current
AccountsPayableAndAccruedLiabilitiesCurrent
1771111 USD
CY2013Q4 us-gaap Accounts Payable And Accrued Liabilities Current
AccountsPayableAndAccruedLiabilitiesCurrent
1662058 USD
CY2014Q1 us-gaap Long Term Debt Current
LongTermDebtCurrent
2849812 USD
CY2013Q4 us-gaap Long Term Debt Current
LongTermDebtCurrent
2763121 USD
CY2014Q1 us-gaap Derivative Liabilities Current
DerivativeLiabilitiesCurrent
0 USD
CY2013Q4 us-gaap Derivative Liabilities Current
DerivativeLiabilitiesCurrent
1417527 USD
CY2014Q1 us-gaap Other Liabilities Current
OtherLiabilitiesCurrent
53280 USD
CY2013Q4 us-gaap Other Liabilities Current
OtherLiabilitiesCurrent
93426 USD
CY2014Q1 us-gaap Liabilities Current
LiabilitiesCurrent
4674203 USD
CY2013Q4 us-gaap Liabilities Current
LiabilitiesCurrent
5936132 USD
CY2014Q1 us-gaap Long Term Debt Noncurrent
LongTermDebtNoncurrent
4192538 USD
CY2013Q4 us-gaap Long Term Debt Noncurrent
LongTermDebtNoncurrent
4934210 USD
CY2014Q1 us-gaap Liabilities Other Than Longterm Debt Noncurrent
LiabilitiesOtherThanLongtermDebtNoncurrent
160338 USD
CY2013Q4 us-gaap Liabilities Other Than Longterm Debt Noncurrent
LiabilitiesOtherThanLongtermDebtNoncurrent
124995 USD
CY2014Q1 us-gaap Liabilities
Liabilities
9027079 USD
CY2013Q4 us-gaap Liabilities
Liabilities
10995337 USD
CY2014Q1 us-gaap Commitments And Contingencies
CommitmentsAndContingencies
USD
CY2013Q4 us-gaap Commitments And Contingencies
CommitmentsAndContingencies
USD
CY2014Q1 us-gaap Preferred Stock Value
PreferredStockValue
0 USD
CY2013Q4 us-gaap Preferred Stock Value
PreferredStockValue
0 USD
CY2013Q4 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-128426037 USD
CY2014Q1 us-gaap Stockholders Equity
StockholdersEquity
26896717 USD
CY2014Q1 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-134345094 USD
CY2013Q4 us-gaap Stockholders Equity
StockholdersEquity
8418199 USD
CY2014Q1 us-gaap Liabilities And Stockholders Equity
LiabilitiesAndStockholdersEquity
35923796 USD
CY2013Q4 us-gaap Liabilities And Stockholders Equity
LiabilitiesAndStockholdersEquity
19413536 USD
CY2013Q1 us-gaap Debt Instrument Carrying Amount
DebtInstrumentCarryingAmount
8000000 USD
CY2013Q1 us-gaap Debt Instrument Unused Borrowing Capacity Amount
DebtInstrumentUnusedBorrowingCapacityAmount
2000000 USD
CY2013Q4 us-gaap Debt Instrument Interest Rate At Period End
DebtInstrumentInterestRateAtPeriodEnd
0.11 pure
CY2014Q1 us-gaap Debt Instrument Maturity Date
DebtInstrumentMaturityDate
2016-06-30
CY2013Q4 us-gaap Preferred Stock Shares Outstanding
PreferredStockSharesOutstanding
0 shares
CY2014Q1 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.01
CY2013Q4 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.01
CY2014Q1 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
150000000 shares
CY2013Q4 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
150000000 shares
CY2014Q1 us-gaap Common Stock Shares Outstanding
CommonStockSharesOutstanding
86688613 shares
CY2013Q4 us-gaap Common Stock Shares Outstanding
CommonStockSharesOutstanding
77886031 shares
CY2014Q1 cur Policy For Maximum Maturity Days Of Investments Considered As Cash Equivalents
PolicyForMaximumMaturityDaysOfInvestmentsConsideredAsCashEquivalents
P90D
CY2013Q1 us-gaap Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount
AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
37400000 shares
CY2014Q1 us-gaap Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount
AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
39800000 shares
CY2014Q1 us-gaap Preferred Stock Shares Authorized
PreferredStockSharesAuthorized
7000000 shares
CY2013Q4 us-gaap Preferred Stock Shares Authorized
PreferredStockSharesAuthorized
7000000 shares
CY2014Q1 us-gaap Preferred Stock Shares Issued
PreferredStockSharesIssued
0 shares
CY2013Q4 us-gaap Preferred Stock Shares Issued
PreferredStockSharesIssued
0 shares
CY2014Q1 us-gaap Preferred Stock Shares Outstanding
PreferredStockSharesOutstanding
0 shares
CY2014Q1 cur Debt Instrument Weighted Average Interest Rate
DebtInstrumentWeightedAverageInterestRate
0.11 pure
CY2014Q1 us-gaap Proceeds From Debt Net Of Issuance Costs
ProceedsFromDebtNetOfIssuanceCosts
7551000 USD
CY2013Q4 us-gaap Debt Default Longterm Debt Amount
DebtDefaultLongtermDebtAmount
300000 USD
CY2014Q1 us-gaap Share Based Compensation
ShareBasedCompensation
2440999 USD
CY2013Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber
18577207 shares
CY2014Q1 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod
408482 shares
CY2014Q1 us-gaap Stock Issued During Period Shares Stock Options Exercised
StockIssuedDuringPeriodSharesStockOptionsExercised
304097 shares
CY2014Q1 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Forfeitures In Period
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod
220903 shares
CY2014Q1 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber
18460689 shares
CY2014Q1 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Exercisable Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber
12895445 shares
CY2014Q1 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Vested And Expected To Vest Outstanding Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber
18460689 shares
CY2013Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice
1.79
CY2014Q1 us-gaap Share Based Compensation Arrangements By Share Based Payment Award Options Grants In Period Weighted Average Exercise Price
ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice
3.22
CY2014Q1 us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Options Vested And Expected To Vest Outstanding Weighted Average Remaining Contractual Term1
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1
P5Y9M18D
CY2013Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Intrinsic Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue
24000710 USD
CY2014Q1 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Intrinsic Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue
43269029 USD
CY2014Q1 us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Options Exercisable Intrinsic Value1
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1
26589447 USD
CY2014Q1 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Vested And Expected To Vest Outstanding Aggregate Intrinsic Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue
43269029 USD
CY2014Q1 us-gaap Share Based Compensation Shares Authorized Under Stock Option Plans Exercise Price Range Number Of Outstanding Options
ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions
18460689 shares
CY2014Q1 cur Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Remaining Contractual Terms
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerms
P5Y9M18D
CY2013Q1 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Dividend Rate
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate
0 pure
CY2014Q1 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Dividend Rate
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate
0 pure
CY2013Q1 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Weighted Average Grant Date Fair Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue
0.69
CY2014Q1 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Weighted Average Grant Date Fair Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue
2.09
CY2013Q1 cur Warrants Issued During Period
WarrantsIssuedDuringPeriod
258000 shares
CY2013Q1 cur Class Of Warrant Or Right Exercise Price Of Warrants Issued
ClassOfWarrantOrRightExercisePriceOfWarrantsIssued
1.25
CY2013Q1 us-gaap Share Price
SharePrice
1.25
CY2013Q2 us-gaap Share Price
SharePrice
1.07
CY2013Q1 cur Stock Issued During Period Share From Warrants In Conjunction With Debt Transaction
StockIssuedDuringPeriodShareFromWarrantsInConjunctionWithDebtTransaction
1297607 shares
CY2013Q1 cur Warrants And Shares Issued Value Net
WarrantsAndSharesIssuedValueNet
323000 USD
CY2013Q1 us-gaap Stock Issued During Period Shares New Issues
StockIssuedDuringPeriodSharesNewIssues
350650 shares
CY2013Q1 cur Stock Issued During Period Share From Warrants Exercised
StockIssuedDuringPeriodShareFromWarrantsExercised
258000 shares
CY2013Q2 cur Stock Issued During Period Share From Warrants Exercised
StockIssuedDuringPeriodShareFromWarrantsExercised
440000 shares
CY2013Q1 cur Warrants Expiration Date
WarrantsExpirationDate
2020-03-31
CY2014Q1 us-gaap Share Based Compensation Arrangements By Share Based Payment Award Options Exercises In Period Weighted Average Exercise Price
ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice
1.44
CY2014Q1 us-gaap Share Based Compensation Arrangements By Share Based Payment Award Options Forfeitures In Period Weighted Average Exercise Price
ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice
0.62
CY2014Q1 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice
1.85
CY2014Q1 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Exercisable Weighted Average Exercise Price
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice
2.13
CY2014Q1 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Vested And Expected To Vest Outstanding Weighted Average Exercise Price
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice
1.85
CY2013 us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Options Outstanding Weighted Average Remaining Contractual Term2
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2
P5Y9M18D
CY2014Q1 us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Options Outstanding Weighted Average Remaining Contractual Term2
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2
P5Y9M18D
CY2014Q1 us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Options Exercisable Weighted Average Remaining Contractual Term1
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1
P4Y7M6D
CY2013Q1 us-gaap Class Of Warrant Or Right Exercise Price Of Warrants Or Rights
ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights
1.25
CY2013Q3 cur Warrants Forfeited During Period
WarrantsForfeitedDuringPeriod
650000 shares
CY2014Q1 us-gaap Stock Option Plan Expense
StockOptionPlanExpense
4857000 USD
CY2014Q1 cur Compensation Expenses Unvested Stock Option Term Period
CompensationExpensesUnvestedStockOptionTermPeriod
P2Y8M12D
CY2014Q1 cur Compensation Expenses Unvested Restricted Stock Term Period
CompensationExpensesUnvestedRestrictedStockTermPeriod
P9M18D
CY2013Q1 us-gaap Revenues
Revenues
102500 USD
CY2014Q1 us-gaap Revenues
Revenues
4167 USD
CY2013Q1 us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
1748347 USD
CY2014Q1 us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
1571221 USD
CY2013Q1 us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
1195840 USD
CY2014Q1 us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
3519359 USD
CY2013Q1 us-gaap Depreciation And Amortization
DepreciationAndAmortization
50093 USD
CY2014Q1 us-gaap Depreciation And Amortization
DepreciationAndAmortization
90488 USD
CY2013Q1 us-gaap Operating Expenses
OperatingExpenses
2994280 USD
CY2014Q1 us-gaap Operating Expenses
OperatingExpenses
5181068 USD
CY2013Q1 us-gaap Operating Income Loss
OperatingIncomeLoss
-2891780 USD
CY2014Q1 us-gaap Operating Income Loss
OperatingIncomeLoss
-5176901 USD
CY2013Q1 us-gaap Investment Income Interest
InvestmentIncomeInterest
9925 USD
CY2014Q1 us-gaap Investment Income Interest
InvestmentIncomeInterest
24718 USD
CY2013Q1 us-gaap Interest Expense
InterestExpense
48257 USD
CY2014Q1 us-gaap Interest Expense
InterestExpense
432741 USD
CY2013Q1 cur Warrant Modification Expense
WarrantModificationExpense
666736 USD
CY2014Q1 cur Warrant Modification Expense
WarrantModificationExpense
0 USD
CY2014Q1 us-gaap Fair Value Adjustment Of Warrants
FairValueAdjustmentOfWarrants
334133 USD
CY2014Q1 us-gaap Short Term Investments
ShortTermInvestments
15000000 USD
CY2013Q4 us-gaap Short Term Investments
ShortTermInvestments
0 USD
CY2013Q1 us-gaap Other Income
OtherIncome
243 USD
CY2014Q1 us-gaap Other Income
OtherIncome
0 USD
CY2014Q1 dei Document Type
DocumentType
10-Q
CY2014Q1 dei Amendment Flag
AmendmentFlag
false
CY2013Q1 us-gaap Payments To Acquire Investments
PaymentsToAcquireInvestments
0 USD
CY2014Q1 us-gaap Payments To Acquire Investments
PaymentsToAcquireInvestments
15000000 USD
CY2014Q1 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Exercises In Period Total Intrinsic Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue
1247250 USD
CY2014Q1 dei Document Period End Date
DocumentPeriodEndDate
2014-03-31
CY2014Q1 dei Document Fiscal Year Focus
DocumentFiscalYearFocus
2014
CY2014Q1 dei Document Fiscal Period Focus
DocumentFiscalPeriodFocus
Q1
CY2013Q1 us-gaap Increase Decrease In Other Noncurrent Liabilities
IncreaseDecreaseInOtherNoncurrentLiabilities
-2605 USD
CY2014Q1 us-gaap Increase Decrease In Other Noncurrent Liabilities
IncreaseDecreaseInOtherNoncurrentLiabilities
-3231 USD
CY2013Q1 us-gaap Net Cash Provided By Used In Operating Activities Continuing Operations
NetCashProvidedByUsedInOperatingActivitiesContinuingOperations
-2512728 USD
CY2014Q1 us-gaap Net Cash Provided By Used In Operating Activities Continuing Operations
NetCashProvidedByUsedInOperatingActivitiesContinuingOperations
-2712824 USD
CY2013Q1 us-gaap Payments To Acquire Intangible Assets
PaymentsToAcquireIntangibleAssets
95161 USD
CY2014Q1 us-gaap Payments To Acquire Intangible Assets
PaymentsToAcquireIntangibleAssets
112068 USD
CY2013Q1 us-gaap Nonoperating Income Expense
NonoperatingIncomeExpense
-698307 USD
CY2014Q1 us-gaap Nonoperating Income Expense
NonoperatingIncomeExpense
-742156 USD
CY2013Q1 us-gaap Net Income Loss
NetIncomeLoss
-3590087 USD
CY2014Q1 us-gaap Net Income Loss
NetIncomeLoss
-5919057 USD
CY2013Q1 us-gaap Earnings Per Share Basic And Diluted
EarningsPerShareBasicAndDiluted
-0.05
CY2014Q1 us-gaap Earnings Per Share Basic And Diluted
EarningsPerShareBasicAndDiluted
-0.07
CY2013Q1 us-gaap Weighted Average Number Of Share Outstanding Basic And Diluted
WeightedAverageNumberOfShareOutstandingBasicAndDiluted
68700709 shares
CY2014Q1 us-gaap Weighted Average Number Of Share Outstanding Basic And Diluted
WeightedAverageNumberOfShareOutstandingBasicAndDiluted
85750298 shares
CY2013Q1 us-gaap Other Comprehensive Income Loss Foreign Currency Transaction And Translation Adjustment Before Tax
OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentBeforeTax
0 USD
CY2014Q1 us-gaap Other Comprehensive Income Loss Foreign Currency Transaction And Translation Adjustment Before Tax
OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentBeforeTax
-1264 USD
CY2013Q1 us-gaap Other Comprehensive Income Loss Before Tax Portion Attributable To Parent
OtherComprehensiveIncomeLossBeforeTaxPortionAttributableToParent
-3590087 USD
CY2014Q1 us-gaap Other Comprehensive Income Loss Before Tax Portion Attributable To Parent
OtherComprehensiveIncomeLossBeforeTaxPortionAttributableToParent
-5920321 USD
CY2013Q1 us-gaap Amortization Of Deferred Leasing Fees
AmortizationOfDeferredLeasingFees
22903 USD
CY2014Q1 us-gaap Amortization Of Deferred Leasing Fees
AmortizationOfDeferredLeasingFees
224795 USD
CY2013Q1 us-gaap Increase Decrease In Accounts Receivable
IncreaseDecreaseInAccountsReceivable
100922 USD
CY2014Q1 us-gaap Increase Decrease In Accounts Receivable
IncreaseDecreaseInAccountsReceivable
1359 USD
CY2013Q1 us-gaap Increase Decrease In Prepaid Expense
IncreaseDecreaseInPrepaidExpense
18325 USD
CY2014Q1 us-gaap Increase Decrease In Prepaid Expense
IncreaseDecreaseInPrepaidExpense
64963 USD
CY2013Q1 us-gaap Increase Decrease In Accounts Payable And Accrued Liabilities
IncreaseDecreaseInAccountsPayableAndAccruedLiabilities
-11321 USD
CY2014Q1 us-gaap Increase Decrease In Accounts Payable And Accrued Liabilities
IncreaseDecreaseInAccountsPayableAndAccruedLiabilities
184745 USD
CY2013Q1 us-gaap Increase Decrease In Other Current Liabilities
IncreaseDecreaseInOtherCurrentLiabilities
607 USD
CY2014Q1 us-gaap Increase Decrease In Other Current Liabilities
IncreaseDecreaseInOtherCurrentLiabilities
626 USD
CY2013Q1 us-gaap Payments To Acquire Property Plant And Equipment
PaymentsToAcquirePropertyPlantAndEquipment
1656 USD
CY2014Q1 us-gaap Payments To Acquire Property Plant And Equipment
PaymentsToAcquirePropertyPlantAndEquipment
111087 USD
CY2013Q1 us-gaap Net Cash Provided By Used In Investing Activities Continuing Operations
NetCashProvidedByUsedInInvestingActivitiesContinuingOperations
-96817 USD
CY2014Q1 us-gaap Net Cash Provided By Used In Investing Activities Continuing Operations
NetCashProvidedByUsedInInvestingActivitiesContinuingOperations
-15223155 USD
CY2013Q1 us-gaap Proceeds From Issuance Or Sale Of Equity
ProceedsFromIssuanceOrSaleOfEquity
322500 USD
CY2014Q1 us-gaap Proceeds From Issuance Or Sale Of Equity
ProceedsFromIssuanceOrSaleOfEquity
1391466 USD
CY2013Q1 us-gaap Proceeds From Issuance Of Private Placement
ProceedsFromIssuanceOfPrivatePlacement
0 USD
CY2014Q1 us-gaap Proceeds From Issuance Of Private Placement
ProceedsFromIssuanceOfPrivatePlacement
19101034 USD
CY2013Q1 us-gaap Proceeds From Issuance Of Long Term Debt
ProceedsFromIssuanceOfLongTermDebt
7551329 USD
CY2014Q1 us-gaap Proceeds From Issuance Of Long Term Debt
ProceedsFromIssuanceOfLongTermDebt
0 USD
CY2013Q1 us-gaap Net Cash Provided By Used In Financing Activities Continuing Operations
NetCashProvidedByUsedInFinancingActivitiesContinuingOperations
7825012 USD
CY2014Q1 us-gaap Net Cash Provided By Used In Financing Activities Continuing Operations
NetCashProvidedByUsedInFinancingActivitiesContinuingOperations
19433698 USD
CY2013Q1 us-gaap Effect Of Exchange Rate On Cash
EffectOfExchangeRateOnCash
0 USD
CY2014Q1 us-gaap Effect Of Exchange Rate On Cash
EffectOfExchangeRateOnCash
-1035 USD
CY2013Q1 us-gaap Cash And Cash Equivalents Period Increase Decrease
CashAndCashEquivalentsPeriodIncreaseDecrease
5215467 USD
CY2014Q1 us-gaap Cash And Cash Equivalents Period Increase Decrease
CashAndCashEquivalentsPeriodIncreaseDecrease
1496684 USD
CY2012Q4 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
7443773 USD
CY2013Q1 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
12659240 USD
CY2013Q1 us-gaap Interest Paid
InterestPaid
910 USD
CY2014Q1 us-gaap Interest Paid
InterestPaid
214622 USD
CY2013Q1 cur Issuance Of Common Stock For Cashless Excercise Of Warrants
IssuanceOfCommonStockForCashlessExcerciseOfWarrants
0 USD
CY2014Q1 cur Issuance Of Common Stock For Cashless Excercise Of Warrants
IssuanceOfCommonStockForCashlessExcerciseOfWarrants
819463 USD
CY2013Q1 cur Issuance Of Warrants For Fees Related To Debt Issuance
IssuanceOfWarrantsForFeesRelatedToDebtIssuance
452187 USD
CY2014Q1 cur Issuance Of Warrants For Fees Related To Debt Issuance
IssuanceOfWarrantsForFeesRelatedToDebtIssuance
0 USD
CY2013Q1 cur Issuance Of Common Stock Related To Debt Issuance Fees
IssuanceOfCommonStockRelatedToDebtIssuanceFees
396234 USD
CY2014Q1 cur Issuance Of Common Stock Related To Debt Issuance Fees
IssuanceOfCommonStockRelatedToDebtIssuanceFees
0 USD
CY2014Q1 dei Trading Symbol
TradingSymbol
CUR
CY2014Q2 dei Entity Common Stock Shares Outstanding
EntityCommonStockSharesOutstanding
86762455 shares
CY2014Q1 dei Entity Registrant Name
EntityRegistrantName
Neuralstem, Inc.
CY2014Q1 dei Entity Central Index Key
EntityCentralIndexKey
0001357459
CY2014Q1 dei Current Fiscal Year End Date
CurrentFiscalYearEndDate
--12-31
CY2014Q1 dei Entity Filer Category
EntityFilerCategory
Accelerated Filer
CY2013Q1 us-gaap Proceeds From Stock Options Exercised
ProceedsFromStockOptionsExercised
0 USD
CY2014Q1 us-gaap Proceeds From Stock Options Exercised
ProceedsFromStockOptionsExercised
113000 USD
CY2013Q1 us-gaap Repayments Of Long Term Debt
RepaymentsOfLongTermDebt
0 USD
CY2014Q1 us-gaap Repayments Of Long Term Debt
RepaymentsOfLongTermDebt
704818 USD
CY2013Q1 us-gaap Repayments Of Short Term Debt
RepaymentsOfShortTermDebt
48817 USD
CY2014Q1 us-gaap Repayments Of Short Term Debt
RepaymentsOfShortTermDebt
40772 USD
CY2013Q1 cur Payment Of Employee Taxes On Stock Option Exercise
PaymentOfEmployeeTaxesOnStockOptionExercise
0 USD
CY2014Q1 cur Payment Of Employee Taxes On Stock Option Exercise
PaymentOfEmployeeTaxesOnStockOptionExercise
426212 USD
CY2013Q1 us-gaap Adjustment Of Warrants Granted For Services
AdjustmentOfWarrantsGrantedForServices
6478 USD
CY2014Q1 us-gaap Adjustment Of Warrants Granted For Services
AdjustmentOfWarrantsGrantedForServices
0 USD
CY2013Q1 cur Issuance Of Common Stock For Cash Less Excercise Of Option
IssuanceOfCommonStockForCashLessExcerciseOfOption
0 USD
CY2014Q1 cur Issuance Of Common Stock For Cash Less Excercise Of Option
IssuanceOfCommonStockForCashLessExcerciseOfOption
254200 USD
CY2014Q1 us-gaap Common Stock Capital Shares Reserved For Future Issuance
CommonStockCapitalSharesReservedForFutureIssuance
44500000 shares
CY2014Q1 cur Compensation Expenses Unvested Restricted Stockoutstanding Value
CompensationExpensesUnvestedRestrictedStockoutstandingValue
45000 USD

Files In Submission

Name View Source Status
0001144204-14-029264-index-headers.html Edgar Link pending
0001144204-14-029264-index.html Edgar Link pending
0001144204-14-029264.txt Edgar Link pending
0001144204-14-029264-xbrl.zip Edgar Link pending
cur-20140331.xml Edgar Link completed
cur-20140331.xsd Edgar Link pending
cur-20140331_cal.xml Edgar Link unprocessable
cur-20140331_def.xml Edgar Link unprocessable
cur-20140331_lab.xml Edgar Link unprocessable
cur-20140331_pre.xml Edgar Link unprocessable
FilingSummary.xml Edgar Link unprocessable
Financial_Report.xls Edgar Link pending
Financial_Report.xlsx Edgar Link pending
R1.htm Edgar Link pending
R10.htm Edgar Link pending
R11.htm Edgar Link pending
R12.htm Edgar Link pending
R13.htm Edgar Link pending
R14.htm Edgar Link pending
R15.htm Edgar Link pending
R16.htm Edgar Link pending
R17.htm Edgar Link pending
R18.htm Edgar Link pending
R19.htm Edgar Link pending
R2.htm Edgar Link pending
R20.htm Edgar Link pending
R21.htm Edgar Link pending
R22.htm Edgar Link pending
R23.htm Edgar Link pending
R24.htm Edgar Link pending
R25.htm Edgar Link pending
R26.htm Edgar Link pending
R3.htm Edgar Link pending
R4.htm Edgar Link pending
R5.htm Edgar Link pending
R6.htm Edgar Link pending
R7.htm Edgar Link pending
R8.htm Edgar Link pending
R9.htm Edgar Link pending
report.css Edgar Link pending
Show.js Edgar Link pending
v375971_10q.htm Edgar Link pending
v375971_ex31-1.htm Edgar Link pending
v375971_ex32-1.htm Edgar Link pending